Difference between revisions of "Template:Antithrombotics"
Jump to navigation
Jump to search
blackwiki>Anypodetos m (Bypass redirs) |
blackwiki>Ronhjones (use listclass = hlist in navbox as per WP:HLIST) |
||
| Line 1: | Line 1: | ||
{{Navbox | {{Navbox | ||
| name = Antithrombotics | | name = Antithrombotics | ||
| − | | title = [[Antithrombotic]]s ([[thrombolytic drug|thrombolytics]] | + | | title = [[Antithrombotic]]s ([[thrombolytic drug|thrombolytics]] |
| + | |listclass = hlist | ||
| + | * [[anticoagulant]]s and [[antiplatelet drug]]s) ([[ATC code B01|B01]]) | ||
| groupstyle = background:MistyRose; | | groupstyle = background:MistyRose; | ||
| Line 9: | Line 11: | ||
| group1 = [[Glycoprotein IIb/IIIa inhibitors]] | | group1 = [[Glycoprotein IIb/IIIa inhibitors]] | ||
| − | | list1 = [[Abciximab]] | + | | list1 = |
| + | * [[Abciximab]] | ||
| + | * [[Eptifibatide]] | ||
| + | * [[Tirofiban]] | ||
| group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]] | | group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]] | ||
| − | | list2 = ''[[thienopyridine]]s'' ([[Clopidogrel]] | + | | list2 = |
| + | * ''[[thienopyridine]]s'' ([[Clopidogrel]] | ||
| + | * [[Prasugrel]] | ||
| + | * [[Ticlopidine]]) | ||
| + | * ''[[nucleotide]]/[[nucleoside]] analogs'' ([[Cangrelor]] | ||
| + | * [[Elinogrel]] | ||
| + | * [[Ticagrelor]]) | ||
| group3 = [[Prostaglandin analogue]] ([[Prostacyclin|PGI2]]) | | group3 = [[Prostaglandin analogue]] ([[Prostacyclin|PGI2]]) | ||
| − | | list3 = [[Beraprost]] | + | | list3 = |
| + | * [[Beraprost]] | ||
| + | * [[Prostacyclin]] | ||
| + | * [[Iloprost]] | ||
| + | * [[Treprostinil]] | ||
| group4 = [[Mechanism of action of aspirin|COX inhibitors]] | | group4 = [[Mechanism of action of aspirin|COX inhibitors]] | ||
| − | | list4 = [[Aspirin|Acetylsalicylic acid/Aspirin]]<sup>#</sup> | + | | list4 = |
| + | * [[Aspirin|Acetylsalicylic acid/Aspirin]]<sup>#</sup> | ||
| + | * [[Aloxiprin]] | ||
| + | * [[Carbasalate calcium]] | ||
| + | * [[Indobufen]] | ||
| + | * [[Triflusal]] | ||
| group5 = [[Thromboxane inhibitors]] | | group5 = [[Thromboxane inhibitors]] | ||
| − | | list5 = ''[[thromboxane synthase inhibitors]]'' ([[Dipyridamole]] | + | | list5 = |
| + | * ''[[thromboxane synthase inhibitors]]'' ([[Dipyridamole]] | ||
| + | * [[Picotamide]]) | ||
| + | * ''[[Thromboxane receptor antagonist|receptor antagonist]]'' ([[Terutroban]]<sup>†</sup>) | ||
| group6 = [[Phosphodiesterase inhibitor]]s | | group6 = [[Phosphodiesterase inhibitor]]s | ||
| − | | list6 = [[Cilostazol]] | + | | list6 = |
| + | * [[Cilostazol]] | ||
| + | * [[Dipyridamole]] | ||
| + | * [[Triflusal]] | ||
| group7 = Other | | group7 = Other | ||
| − | | list7 = [[Cloricromen]] | + | | list7 = |
| + | * [[Cloricromen]] | ||
| + | * [[Ditazole]] | ||
}} | }} | ||
| Line 35: | Line 63: | ||
| groupstyle = background-color: MistyRose | | groupstyle = background-color: MistyRose | ||
| − | | group1 = [[Vitamin K antagonist]]s<br />(inhibit [[Thrombin|II]], [[Factor VII|VII]], [[Factor IX|IX]], [[Factor X|X]]) | + | | group1 = [[Vitamin K antagonist]]s<br />(inhibit [[Thrombin|II]], [[Factor VII|VII]], [[Factor IX|IX]], [[Factor X|X]]) |
| − | | list1 = ''[[coumarin]]s:'' [[Acenocoumarol]] | + | | list1 = |
| + | * ''[[coumarin]]s:'' [[Acenocoumarol]] | ||
| + | * [[Coumatetralyl]] | ||
| + | * [[Dicoumarol]] | ||
| + | * [[Ethyl biscoumacetate]] | ||
| + | * [[Phenprocoumon]] | ||
| + | * [[Warfarin]]<sup>#</sup> | ||
| − | ''[[1,3-Indandione]]s:'' [[Clorindione]] | + | *''[[1,3-Indandione]]s:'' [[Clorindione]] |
| + | * [[Diphenadione]] | ||
| + | * [[Phenindione]] | ||
''other:'' [[Tioclomarol]] | ''other:'' [[Tioclomarol]] | ||
| Line 47: | Line 83: | ||
| group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]]) | | group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]]) | ||
| − | | list1 = ''[[low-molecular-weight heparin]]'' ([[Bemiparin sodium|Bemiparin]] | + | | list1 = |
| + | * ''[[low-molecular-weight heparin]]'' ([[Bemiparin sodium|Bemiparin]] | ||
| + | * [[Certoparin sodium|Certoparin]] | ||
| + | * [[Dalteparin sodium|Dalteparin]] | ||
| + | * [[Enoxaparin sodium|Enoxaparin]] | ||
| + | * [[Nadroparin calcium|Nadroparin]] | ||
| + | * [[Parnaparin sodium|Parnaparin]] | ||
| + | * [[Reviparin sodium|Reviparin]] | ||
| + | * [[Tinzaparin sodium|Tinzaparin]]) | ||
| − | ''[[oligosaccharide]]s'' ([[Fondaparinux]] | + | *''[[oligosaccharide]]s'' ([[Fondaparinux]] |
| + | * [[Idraparinux]]) | ||
| − | ''[[heparinoid]]'' ([[Danaparoid]] | + | *''[[heparinoid]]'' ([[Danaparoid]] |
| + | * [[Sulodexide]] | ||
| + | * [[Dermatan sulfate]]) | ||
| group7 = [[Direct Xa inhibitor]]s | | group7 = [[Direct Xa inhibitor]]s | ||
| − | | list7 = ''xabans'' ([[Apixaban]] | + | | list7 = |
| + | * ''xabans'' ([[Apixaban]] | ||
| + | * [[Betrixaban]] | ||
| + | * [[Edoxaban]] | ||
| + | * [[Otamixaban]] | ||
| + | * [[Rivaroxaban]]) | ||
}} | }} | ||
| group6 = [[Direct thrombin inhibitor|Direct thrombin (II) inhibitor]]s | | group6 = [[Direct thrombin inhibitor|Direct thrombin (II) inhibitor]]s | ||
| − | | list6 = ''[[Direct_thrombin_inhibitor#Bivalent|bivalent]]:'' [[Hirudin]] ([[Bivalirudin]] | + | | list6 = |
| + | * ''[[Direct_thrombin_inhibitor#Bivalent|bivalent]]:'' [[Hirudin]] ([[Bivalirudin]] | ||
| + | * [[Lepirudin]] | ||
| + | * [[Desirudin]])<br /> | ||
| − | ''[[Direct_thrombin_inhibitor#Univalent|univalent]]:'' [[Argatroban]] | + | *''[[Direct_thrombin_inhibitor#Univalent|univalent]]:'' [[Argatroban]] |
| + | * [[Dabigatran]] | ||
| + | * [[Melagatran]]<sup>‡</sup> | ||
| + | * [[Ximelagatran]]<sup>‡</sup> | ||
| group8 = Other | | group8 = Other | ||
| − | | list8 = [[REG1<!--instantly reversible aptamer-based direct FIXa inhibitor in IIb trials -->]] | + | | list8 = |
| + | * [[REG1<!--instantly reversible aptamer-based direct FIXa inhibitor in IIb trials -->]] | ||
| + | * [[Defibrotide]] | ||
| + | * [[Ramatroban]] | ||
| + | * [[Antithrombin|Antithrombin III]] | ||
| + | * [[Protein C]] ([[Drotrecogin alfa]]) | ||
}} | }} | ||
| group5 = [[Thrombolytic drug]]s/<br />[[fibrinolytic]]s | | group5 = [[Thrombolytic drug]]s/<br />[[fibrinolytic]]s | ||
| − | | list5 = ''[[plasminogen activator]]s:'' ''[[recombinant tissue plasminogen activators|r-tPA]]'' ([[Tissue plasminogen activator|Alteplase]] | + | | list5 = |
| + | * ''[[plasminogen activator]]s:'' ''[[recombinant tissue plasminogen activators|r-tPA]]'' ([[Tissue plasminogen activator|Alteplase]] | ||
| + | * [[Reteplase]] | ||
| + | * [[Tenecteplase]]) | ||
| + | * ''UPA'' ([[Urokinase]] | ||
| + | * [[Saruplase]]) | ||
| + | * [[Streptokinase]]<sup>#</sup> | ||
| + | * [[Anistreplase]] | ||
| + | * [[Monteplase]] | ||
| − | ''other [[serine endopeptidase]]s:'' [[Ancrod]] | + | *''other [[serine endopeptidase]]s:'' [[Ancrod]] |
| − | + | * [[Fibrinolysin]] | |
| − | [[Brinase]] | + | * [[Brinase]] |
| group8 = [[Anticoagulant#Anticoagulants outside the body|Non-medicinal]] | | group8 = [[Anticoagulant#Anticoagulants outside the body|Non-medicinal]] | ||
| − | | list8 = [[Citrate]] | + | | list8 = |
| + | * [[Citrate]] | ||
| + | * [[EDTA]] | ||
| + | * [[Oxalate]] | ||
| group9 = | | group9 = | ||
| Line 87: | Line 161: | ||
}}<noinclude> | }}<noinclude> | ||
[[Category:Antithrombotic agents]] | [[Category:Antithrombotic agents]] | ||
| − | [[Category:Drug_templates by ATC | + | [[Category:Drug_templates by ATC]] |
[[hu:Sablon:Antitrombotikumok]] | [[hu:Sablon:Antitrombotikumok]] | ||
[[pt:Predefinição:Antitrombóticos]] | [[pt:Predefinição:Antitrombóticos]] | ||
[[zh:Template:抗血栓药]] | [[zh:Template:抗血栓药]] | ||
</noinclude> | </noinclude> | ||